採用
Job Description:
主要职责1. 品牌策略(Brand Strategy)
-
基于中国糖尿病诊疗特点、指南更新、治疗路径、临床需求,内外部竞争环境,制定品牌定位与价值主张。
-
识别与竞争产品的差异化空间,主导年度品牌策略(Brand Plan),并制定落地计划。
2. 卓越推广(Execution Excellence)
-
主导核心品牌故事及关键信息
-
设计并打造高影响力项目平台,推动其在重点城市、重点科室及重点患者人群中的渗透率增长
-
确保所有活动严格遵守医药相关法规与公司政策。
3. 关键客户管理及洞察(Insight & Engagement)
-
深入理解不同层级医院及科室在糖尿病管理中的不 同需求与痛点,将洞察转化为可执行策略。
-
建立并强化与关键专家(KOL)、指南委员会成员、学会平台的合作。
-
推动跨团队合作(Sales、Medical 、CE、BE等)共同打造品牌价值
4. 数据驱动(Data-Driven)
-
持续跟进品牌关键指标(业务达成、增长、份额、客户观念等与年度策略保持一致),推动业务增长与资源优化。
-
根据销售数据、竞争情报(CI)、客户观念等工具,不断优化品牌策略。
任职要求教育背景
- 本科及以上学历,医学、药学、 生命科学、公共卫生或商业相关专业优先。
要求
-
3 年以上医药行业慢病中央市场部产品管理经验,糖尿病或代谢疾病经验优先
-
有增长期品牌管理、竞争格局激烈产品的差异化打造经验者优先
-
精通推广活动设计、HCP 教育策略
-
优秀的跨团队协作与影响力。
软技能要求
-
自驱力强,具备高度责任心与韧 性。
-
逻辑清晰、沟通表达专业有力。
-
优秀的项目管理与多任务并行能力。
-
高度合规意识。
Required Skills:
Adaptability, Adaptability, Brand Management, Brand Strategy, Clinical Pathways, Content Creation, Creativity, Cross-Functional Leadership, Cross-Team Collaboration, Customer Insights, Diabetes Mellitus, Digital Consumer Engagement, Digital Marketing, Health Sciences, Hypothermia, Market Research, Market Segmentation, Medical Care, Medicare Guidelines, Omnichannel Marketing, Pharmaceutical Compliance, Pharmaceutical Management, Pharmacology, Product Launches, Product Management {+ 2 more}
Preferred Skills:
Current Employees apply HERE
Current Contingent Workers apply HERE
Search Firm Representatives Please Read Carefully
Merck & Co., Inc., Rahway, NJ, USA, also known as Merck Sharp & Dohme LLC, Rahway, NJ, USA, does not accept unsolicited assistance from search firms for employment opportunities. All CVs / resumes submitted by search firms to any employee at our company without a valid written search agreement in place for this position will be deemed the sole property of our company. No fee will be paid in the event a candidate is hired by our company as a result of an agency referral where no pre-existing agreement is in place. Where agency agreements are in place, introductions are position specific. Please, no phone calls or emails.
Employee Status:
Regular
Relocation:
No relocation
VISA Sponsorship:
No
Travel Requirements:
25%
Flexible Work Arrangements:
Not Applicable
Shift:
Not Indicated
Valid Driving License:
No
Hazardous Material(s):
na
Job Posting End Date:
07/31/2026
**A job posting is effective until 11:59:59PM on the day BEFORE the listed job posting end date. Please ensure you apply to a job posting no later than the day BEFORE the job posting end date.
総閲覧数
0
応募クリック数
0
模擬応募者数
0
スクラップ
0
類似の求人

Program Operations, Maritime
Anduril · Costa Mesa, California, United States

Responsable de la transformation numérique (H/F)
Aptiv · Epernon, France

Program Cost and Schedule Control Analyst - Level 2 or 3
Northrop Grumman · United States-Utah-Corinne; United States-Utah-Magna

Project Engineer
Curtiss-Wright · Neogen Ionics Limited

Agile Project Resource – Network Architecture & Governance
Luxoft (DXC) · NZL - AUK - AUCKLAND
Merckについて

Merck
PublicMultinational pharmaceutical company.
10,001+
従業員数
Rahway
本社所在地
$208B
企業価値
レビュー
4.3
10件のレビュー
ワークライ フバランス
4.0
報酬
3.5
企業文化
4.2
キャリア
3.8
経営陣
4.0
78%
友人に勧める
良い点
Supportive management and colleagues
Good work-life balance and flexibility
Excellent benefits and health plans
改善点
High-pressure and demanding work environment
Limited career advancement opportunities
Below-average pay for entry-level positions
給与レンジ
2,504件のデータ
Junior/L3
Director
Junior/L3 · Product Manager
0件のレポート
$156,500
年収総額
基本給
-
ストック
-
ボーナス
-
$133,025
$179,975
面接体験
6件の面接
難易度
3.0
/ 5
期間
14-28週間
内定率
17%
体験
ポジティブ 0%
普通 67%
ネガティブ 33%
面接プロセス
1
Application Review
2
HR Screen
3
Hiring Manager Interview
4
Panel Interview
5
Background Check
6
Offer
よくある質問
Behavioral/STAR
Past Experience
Technical Knowledge
Culture Fit
Case Study
ニュース&話題
Merck Unveils First-in-Human Data for PD-1/VEGF Bispecific MK-2010 - Oncodaily
Oncodaily
News
·
3d ago
Does EU Approval Of ENFLONSIA Reshape The Bull Case For Merck’s Pipeline Story (MRK)? - Yahoo Finance
Yahoo Finance
News
·
3d ago
Better Pharma Dividend Stock: Novartis vs. Merck - The Motley Fool
The Motley Fool
News
·
3d ago
AACR: Merck unveils PD-1xVEGF bispecific data in NSCLC, remains tight-lipped on phase 3 plans - Fierce Biotech
Fierce Biotech
News
·
3d ago